Critical issues include: (i) heterogeneity in stem
cell populations (ii) regulation of
cell fate choices; (iii)
declining tissue performance with age and exposure to environmental injuries; (iv) the use of iPS and Embryonic Stem (ES)
cells, and reprogramming methods for phenotyping disease states and potential use of these stem
cells in the clinic.